Diagnostic role of 18F-fluorodeoxyglucose positron emission tomography for follicular lymphoma with gastrointestinal involvement

Table 1 Accumulation of 18F-fluorodeoxyglucose detected in the gastrointestinal tract

	Positive involvement (defined by endoscopy)	True-positive 18F-FDG uptake	False-positive 18F-FDG uptake	Sensitivity (%)
Esophagus	0	0	0	NA
Stomach	1	1	1	100.0
Duodenum	34	12	0	35.3
Jejunum	6	5	0	83.3
Ileum	3	1	1	33.3
Cecum	2	2	0	100.0
Colon	3	1	1	33.3
Rectum	6	3	2	50.0

18F-FDG: 18F-fluorodeoxyglucose; NA: Not available.

Table 2 Clinical backgrounds of the study subjects (mean ± SD)

	Negative FDG uptake in GI tract	Positive FDG uptake in GI tract	P value
No. patients (n)	22	19
Male/female	10/12	4/15	0.186
Age (yr) at diagnosis of FL	63.6 ± 2.4	60.1 ± 2.6	0.323
WHO grade			1.000
Grade 1	20	17
Grade 2	2	2
Follicular dendritic cell pattern
Duodenal	13	10	1.000
Nodal	5	3
Mitotic rate			0.311
Low	14	10
Partly high	1	3
Ann Arbor system staging			0.499
IE	12	11
IIE	3	4
IIIES	1	0
IV	6	4
Lugano system staging			0.489
I	12	10
II-1	2	4
II-2	1	1
IV	7	4
sIL-2R	495 ± 78	402 ± 83	0.884
LDH	188 ± 7	183 ± 8	0.749
Hb	13.5 ± 0.3	12.8 ± 0.4	0.197
Bone marrow involvement			1.000
Positive	1	1
Negative	8	10
Detection of GI lesions by CT			0.335
Positive	1	4
Negative	16	13
FLIPI risk			0.763
Low	16	13
Intermediate	3	3
Poor	3	3

FDG: Fluorodeoxyglucose; GI: Gastrointestinal; FL: Follicular lymphoma; sIL-2R: Soluble interleukin-2 receptor; CT: Computed tomography; FLIPI: Follicular lymphoma international prognostic index; LDH: Lactate dehydrogenase; WHO: World Health Organization.